SE0103839D0 - Pharmaceutical formulation & product - Google Patents

Pharmaceutical formulation & product

Info

Publication number
SE0103839D0
SE0103839D0 SE0103839A SE0103839A SE0103839D0 SE 0103839 D0 SE0103839 D0 SE 0103839D0 SE 0103839 A SE0103839 A SE 0103839A SE 0103839 A SE0103839 A SE 0103839A SE 0103839 D0 SE0103839 D0 SE 0103839D0
Authority
SE
Sweden
Prior art keywords
alpha
product
drug
patient
methylpropiono
Prior art date
Application number
SE0103839A
Other languages
English (en)
Inventor
Nicola Bateman
Julie Cahill
Neill Carman
Ian Cockshott
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0103839A priority Critical patent/SE0103839D0/sv
Publication of SE0103839D0 publication Critical patent/SE0103839D0/sv
Priority to TW091132270A priority patent/TW200406200A/zh
Priority to UY27539A priority patent/UY27539A1/es
Priority to MXPA04004591A priority patent/MXPA04004591A/es
Priority to ES02779684T priority patent/ES2278063T3/es
Priority to DE60217390T priority patent/DE60217390T2/de
Priority to KR1020047007359A priority patent/KR20050044468A/ko
Priority to JP2003545287A priority patent/JP2005514355A/ja
Priority to AT02779684T priority patent/ATE350016T1/de
Priority to CNA028272277A priority patent/CN1615122A/zh
Priority to US10/495,012 priority patent/US20050038111A1/en
Priority to ARP020104386A priority patent/AR037390A1/es
Priority to BR0214135-3A priority patent/BR0214135A/pt
Priority to PCT/GB2002/005159 priority patent/WO2003043606A1/en
Priority to EP02779684A priority patent/EP1448168B1/en
Priority to AU2002343024A priority patent/AU2002343024A1/en
Priority to IL16190202A priority patent/IL161902A0/xx
Priority to CA002466986A priority patent/CA2466986A1/en
Priority to ZA200403689A priority patent/ZA200403689B/en
Priority to NO20042502A priority patent/NO20042502L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE0103839A 2001-11-16 2001-11-16 Pharmaceutical formulation & product SE0103839D0 (sv)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SE0103839A SE0103839D0 (sv) 2001-11-16 2001-11-16 Pharmaceutical formulation & product
TW091132270A TW200406200A (en) 2001-11-16 2002-10-31 Pharmaceutical formulation
UY27539A UY27539A1 (es) 2001-11-16 2002-11-13 Formulación farmacéutica
CA002466986A CA2466986A1 (en) 2001-11-16 2002-11-14 Pharmaceutical formulation comprising bicalutamide
AT02779684T ATE350016T1 (de) 2001-11-16 2002-11-14 Bicalutamid enthaltende pharmazeutische zusammensetzung
BR0214135-3A BR0214135A (pt) 2001-11-16 2002-11-14 Produto farmacêutico, dose farmacêutica, usos de um anti-estrogênio e de um inibidor da aromatase e 4'-ciano-alfa', alfa, alfa'-trifluoro-3-(4-fluorofenilsulfonil)-2-hidróxi-2- metilpropiono-m-toluidida ou um sal ou solvato farmaceuticamente aceitáveis destes, e, método para tratar de câncer da próstata e/ou reduzir o risco de câncer da próstata em um paciente
DE60217390T DE60217390T2 (de) 2001-11-16 2002-11-14 Bicalutamid enthaltende pharmazeutische zusammensetzung
KR1020047007359A KR20050044468A (ko) 2001-11-16 2002-11-14 비칼루타미드를 포함하는 약학 제제
JP2003545287A JP2005514355A (ja) 2001-11-16 2002-11-14 ビカルタミドを含んでなる医薬製剤
MXPA04004591A MXPA04004591A (es) 2001-11-16 2002-11-14 Formulacion farmaceutica que contiene bicalutamida.
CNA028272277A CN1615122A (zh) 2001-11-16 2002-11-14 包含比卡鲁胺的药物制剂
US10/495,012 US20050038111A1 (en) 2001-11-16 2002-11-14 Pharmaceutical formulation comprising bicalutamide
ARP020104386A AR037390A1 (es) 2001-11-16 2002-11-14 Formulacion farmaceutica
ES02779684T ES2278063T3 (es) 2001-11-16 2002-11-14 Formulacion farmaceutica que comprende bicalutamida.
PCT/GB2002/005159 WO2003043606A1 (en) 2001-11-16 2002-11-14 Pharmaceutical formulation comprising bicalutamide
EP02779684A EP1448168B1 (en) 2001-11-16 2002-11-14 Pharmaceutical formulation comprising bicalutamide
AU2002343024A AU2002343024A1 (en) 2001-11-16 2002-11-14 Pharmaceutical formulation comprising bicalutamide
IL16190202A IL161902A0 (en) 2001-11-16 2002-11-14 Pharmaceutical formulation comprising bicalutamide
ZA200403689A ZA200403689B (en) 2001-11-16 2004-05-13 Pharmaceutical formulation comprising bicalutamide
NO20042502A NO20042502L (no) 2001-11-16 2004-06-15 Farmasoytisk formulering omfattende bicalutamid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103839A SE0103839D0 (sv) 2001-11-16 2001-11-16 Pharmaceutical formulation & product

Publications (1)

Publication Number Publication Date
SE0103839D0 true SE0103839D0 (sv) 2001-11-16

Family

ID=20286023

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0103839A SE0103839D0 (sv) 2001-11-16 2001-11-16 Pharmaceutical formulation & product

Country Status (20)

Country Link
US (1) US20050038111A1 (sv)
EP (1) EP1448168B1 (sv)
JP (1) JP2005514355A (sv)
KR (1) KR20050044468A (sv)
CN (1) CN1615122A (sv)
AR (1) AR037390A1 (sv)
AT (1) ATE350016T1 (sv)
AU (1) AU2002343024A1 (sv)
BR (1) BR0214135A (sv)
CA (1) CA2466986A1 (sv)
DE (1) DE60217390T2 (sv)
ES (1) ES2278063T3 (sv)
IL (1) IL161902A0 (sv)
MX (1) MXPA04004591A (sv)
NO (1) NO20042502L (sv)
SE (1) SE0103839D0 (sv)
TW (1) TW200406200A (sv)
UY (1) UY27539A1 (sv)
WO (1) WO2003043606A1 (sv)
ZA (1) ZA200403689B (sv)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20032225A3 (cs) * 2001-02-27 2003-11-12 Astrazeneca Ab Farmaceutická formulace
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US7226622B2 (en) 2003-09-18 2007-06-05 Boston Scientific Scimed, Inc. Chemoablation of tissue using biodegradable, solid salt dosage forms
WO2005072462A2 (en) * 2004-01-28 2005-08-11 Charles Shih Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof
AU2005278894A1 (en) 2004-08-31 2006-03-09 Pfizer Products Inc. Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
EP1954263A2 (en) * 2005-02-23 2008-08-13 AstraZeneca AB Composition for increasing steady state plasma levels of bicalutamide
US20080177109A1 (en) * 2005-03-29 2008-07-24 Usv Limited Novel Process for Preparation of Bicalutamide
US20090291134A1 (en) * 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
WO2009105264A1 (en) * 2008-02-21 2009-08-27 Iris International Inc. Method for early determination of recurrence after therapy for prostate cancer
AU2009292615B2 (en) * 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
EP3725778B1 (en) 2012-09-11 2021-08-18 Medivation Prostate Therapeutics LLC Formulations of enzalutamide
CN107049972A (zh) * 2017-03-17 2017-08-18 万特制药(海南)有限公司 一种含有来曲唑固体分散体的分散片及其制备工艺

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3121152A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
JPH09508125A (ja) * 1994-01-21 1997-08-19 セプラコー，インコーポレイテッド 光学的純正ｒ−（−）−カソデックスを使用した男性ホルモン依存疾患治療のための方法と組成
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
US6139875A (en) * 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating

Also Published As

Publication number Publication date
EP1448168A1 (en) 2004-08-25
MXPA04004591A (es) 2004-08-13
EP1448168B1 (en) 2007-01-03
DE60217390T2 (de) 2007-11-15
ATE350016T1 (de) 2007-01-15
BR0214135A (pt) 2004-10-13
ES2278063T3 (es) 2007-08-01
UY27539A1 (es) 2003-07-31
NO20042502L (no) 2004-08-09
AR037390A1 (es) 2004-11-10
IL161902A0 (en) 2005-11-20
TW200406200A (en) 2004-05-01
JP2005514355A (ja) 2005-05-19
WO2003043606A1 (en) 2003-05-30
CN1615122A (zh) 2005-05-11
KR20050044468A (ko) 2005-05-12
ZA200403689B (en) 2006-06-28
DE60217390D1 (de) 2007-02-15
CA2466986A1 (en) 2003-05-30
AU2002343024A1 (en) 2003-06-10
US20050038111A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
SE0103839D0 (sv) Pharmaceutical formulation & product
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
IS6970A (is) Lyfjablanda á föstu formi sem felur í sér 4-sýanó-tríflúor-3-(4-flúorfenýlsúlfonýl)-2-hýdroxý-2-metýlprópíón-m-tólúidíð og PVP
CR8352A (es) Formulaciones farmaceuticas, procedimientos y pautas de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
BR0110877A (pt) Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
UY27186A1 (es) Formulación farmacéutica
UA85359C2 (ru) Таблетка, содержащая гранулированный материал с kmd-3213
EA200501105A1 (ru) Фармацевтическая композиция
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
SE0103424D0 (sv) Pharmaceutical formulation
ATE341319T1 (de) Esmolol-enthaltende zubereitungen
ATE442158T1 (de) Oral verabreichte pharmazeutische zusammensetzungen mit einem abgabemittel in mikronisierter form
SE0103838D0 (sv) Pharmaceutical formulation & product
PE20031047A1 (es) Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama
SE9901572D0 (sv) New compounds
SE0102887D0 (sv) New formulation
MX2009006873A (es) Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida.
SE0102886D0 (sv) New formulation
Thomas Considering Bio/Pharma Reformulation Strategies
RU2003133136A (ru) Новое применение производных арилэтенсульфонамида
JP2017514834A5 (sv)
SE0102888D0 (sv) New formulation
UA144734U (uk) Спосіб лікування вірусних інфекційних захворювань